- Home
- CCEL vs ITRM Comparison
CCEL vs ITRM Comparison
Compare CCEL & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- ITRM
- Stock Information
- Founded
- CCEL 1989
- ITRM 2015
- Country
- CCEL United States
- ITRM Ireland
- Employees
- CCEL N/A
- ITRM N/A
- Industry
- CCEL Managed Health Care
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- ITRM Health Care
- Exchange
- CCEL Nasdaq
- ITRM Nasdaq
- Market Cap
- CCEL 51.9M
- ITRM 37.7M
- IPO Year
- CCEL 1997
- ITRM 2018
- Fundamental
- Price
- CCEL $5.82
- ITRM $1.08
- Analyst Decision
- CCEL Strong Buy
- ITRM Strong Buy
- Analyst Count
- CCEL 1
- ITRM 1
- Target Price
- CCEL $8.50
- ITRM $5.00
- AVG Volume (30 Days)
- CCEL 11.7K
- ITRM 300.3K
- Earning Date
- CCEL 04-15-2025
- ITRM 05-12-2025
- Dividend Yield
- CCEL 4.27%
- ITRM N/A
- EPS Growth
- CCEL N/A
- ITRM N/A
- EPS
- CCEL 0.01
- ITRM N/A
- Revenue
- CCEL $32,102,750.00
- ITRM N/A
- Revenue This Year
- CCEL $2.21
- ITRM N/A
- Revenue Next Year
- CCEL $0.98
- ITRM $150.10
- P/E Ratio
- CCEL $365.46
- ITRM N/A
- Revenue Growth
- CCEL 2.33
- ITRM N/A
- 52 Week Low
- CCEL $4.96
- ITRM $0.81
- 52 Week High
- CCEL $9.50
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- CCEL 44.23
- ITRM 32.84
- Support Level
- CCEL $5.37
- ITRM $1.05
- Resistance Level
- CCEL $5.70
- ITRM $1.16
- Average True Range (ATR)
- CCEL 0.46
- ITRM 0.08
- MACD
- CCEL 0.03
- ITRM -0.00
- Stochastic Oscillator
- CCEL 50.89
- ITRM 13.04
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.